Liver cancer patients get chemo via implantable pump in new safety trial
NCT ID NCT04684862
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a combined pump and catheter system that delivers chemotherapy directly to the liver in adults with colorectal cancer that has spread to the liver or with bile duct cancer. The main goal is to see if the device is safe. About 100 participants will have the pump implanted and be monitored for up to 5 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Medtronic SynchroMed II pump connected to an Intera tapered catheter (device) delivering FUDR chemotherapy
What this could lead to
If this device proves safe and effective, it could offer a more targeted way to deliver chemotherapy to liver tumors, potentially reducing side effects and improving tumor control.
What could go wrong
This is an early safety study with no control group, so it cannot prove the device works better than standard treatment. There are risks from surgery, the pump, and the catheter connection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States